Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?
'Nobel Prize Winners Sitting At Starbucks'
The head of the US arm of a major Korean government development institute talks to Scrip about why biotechs and pharma firms are flocking to Boston, how the organization is providing support and what the main challenges are.
You may also be interested in...
How Do Bioventures Thrive In APAC? Strategies And Risks Beyond Borders
With the global market in sight, several Asian bioventures discussed at BioJapan event recent projects, strategies and challenges in expanding their businesses in APAC. The different characteristics of policies by country and facets of venture capital funding were some of the topics when speakers talked about “what's the ideal collaboration between Asian bioventures?”
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: etrasimod comes through for Pfizer; PTC confident on gene therapy; could CAR-Ts roll into the community setting; the attractions of Boston for Korean bioventures; and Ukraine war may claim Sputnik casualties.
No More Big Fish In A Small Pond: Yuhan Opts For Globalization For Long-Term Growth
After clinching massive licensing-out agreements with multinationals last year, Yuhan is setting out a long-term global road map with a determination that it won’t just remain top in the South Korean market. The head of the firm's newly established global strategy department talks to Scrip how and why it aims to achieve globalization in the next decade and beyond.